STOCK TITAN
  1. Home
  2. SEC-Filings
  3. FTRE

Fortrea Holdings SEC Filings

FTRE NASDAQ

Welcome to our dedicated page for Fortrea Holdings SEC filings (Ticker: FTRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Fortrea Holdings’ emergence as a stand-alone CRO after its Labcorp spin-off means every quarter brings layers of new disclosures—from trial backlog shifts to milestone-based revenue. Hunting for those details in a 200-page filing is why users type “Fortrea SEC filings explained simply” or “where can I find the Fortrea quarterly earnings report 10-Q filing.”

Stock Titan fixes that pain. The moment a 10-K, 10-Q, 8-K, S-8, or DEF 14A posts to EDGAR, our AI turns it into plain English, flags changes in pass-through costs, and links footnotes to context you can act on. Need “Fortrea annual report 10-K simplified,” “Fortrea 8-K material events explained,” or a side-by-side view of Form 4 insider trades? Our platform delivers real-time updates, AI-powered summaries, and historical comparisons—so you see why an event matters, not just that it happened.

Popular use cases include:

  • Tracking “Fortrea insider trading Form 4 transactions” seconds after executives file.
  • Comparing enrolment cost trends straight from MD&A with our Fortrea earnings report filing analysis.
  • Reviewing “Fortrea proxy statement executive compensation” without navigating 100 tables.
Whether you’re “understanding Fortrea SEC documents with AI” before a biotech outsourcing call or watching “Fortrea Form 4 insider transactions real-time” for post-lock-up moves, Stock Titan keeps every disclosure, note, and exhibit one search away—so informed decisions take minutes, not evenings.

Filing

[SCHEDULE 13G/A] Fortrea Holdings Inc. SEC Filing

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing

[SCHEDULE 13G/A] Fortrea Holdings Inc. SEC Filing

Rhea-AI Summary

BlackRock Portfolio Management LLC filed Amendment No. 1 to Schedule 13G for Fortrea Holdings Inc. (FTRE) covering holdings as of 30 Jun 2025. The firm reports beneficial ownership of 804,040 common shares, equal to 0.9 % of outstanding stock, placing the position well below the 5 % threshold that would trigger additional reporting requirements.

BlackRock has sole voting power over 714,353 shares and sole dispositive power over the full 804,040-share stake; it reports no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business, without intent to influence control. Because ownership is under 5 %, the filer confirms compliance with Item 5 and notes that no single client owns more than 5 % of FTRE. The document is certified by Managing Director Spencer Fleming on 15 Jul 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Fortrea Holdings (FTRE)?

The current stock price of Fortrea Holdings (FTRE) is $4.69 as of July 18, 2025.

What is the market cap of Fortrea Holdings (FTRE)?

The market cap of Fortrea Holdings (FTRE) is approximately 477.1M.

What core services does Fortrea Holdings provide?

Fortrea offers comprehensive clinical trial management across Phases I-IV, clinical pharmacology, and consulting services. The company also provides patient access solutions to enhance trial participation and retention.

How does Fortrea generate revenue?

Fortrea generates revenue by partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies on clinical trials and related services. Its revenue streams are primarily derived from service fees for trial management and consulting expertise.

How does Fortrea differentiate itself in the CRO industry?

Fortrea differentiates itself through its global scale, decades of industry expertise, and an integrated approach that combines scientific rigor with advanced technology. Its focus on becoming a pure-play CRO enhances its specialization in clinical trial management.

What is the significance of Fortrea's technological integration?

The company integrates AI and machine learning to optimize processes such as trial simulations and predictive analytics. This technology-driven approach reduces administrative burdens and improves patient safety throughout the clinical trial process.

What industries does Fortrea primarily serve?

Fortrea serves emerging and large-scale biopharmaceutical companies, as well as firms in biotechnology, medical devices, and diagnostics. Its services are designed to meet the diverse needs of the life sciences industry.

How extensive is Fortrea's global presence?

Fortrea operates in over 90 countries, supported by a vast global network of investigator sites and clinical research professionals. This global reach reinforces its ability to manage trials across a multitude of therapeutic areas.

How does Fortrea ensure regulatory and quality compliance?

Fortrea adheres to rigorous quality control measures and risk-based monitoring to meet global regulatory standards. Its systematic approach focuses on maintaining high scientific and operational standards throughout every phase of clinical trials.
Stock FTRE logo
Fortrea Holdings

NASDAQ:FTRE

FTRE Rankings

#3725 Ranked by Market Cap
N/A Ranked by Dividends

FTRE Stock Data

477.15M
90.13M
0.31%
105.63%
7.64%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM